Welcome to our dedicated page for Evolv Technologies Hldngs SEC filings (Ticker: EVLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evolv Technologies Holdings, Inc. filings document the public-company disclosures of an AI-based security screening business with Class A common stock and warrants listed on Nasdaq. Its Form 8-K reports include financial-results releases, Regulation FD disclosures, board and officer changes, stockholder meeting results, credit-agreement disclosures and registration-statement amendments tied to resale securities and warrant exercises.
Proxy materials describe director elections, executive compensation, auditor ratification, board committee matters and shareholder voting procedures. The filings also identify capital-structure elements, including Class A common stock, warrants and subsidiary borrowing arrangements, alongside governance and reporting matters for Evolv’s screening technology operations.
Evolv Technologies Holdings, Inc. reported results of its annual stockholder meeting held on June 18, 2026. A total of 138,936,379 shares of Class A common stock were represented, equal to approximately 77.35% of shares outstanding as of the April 24, 2026 record date.
Stockholders elected Class II directors Neil Glat and Richard Shapiro to serve until the 2029 annual meeting. They also approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, and ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026.
Evolv Technologies Holdings director David Mounts Gonzales exercised restricted stock units that vested on June 17, 2026, converting them into 27,050 shares of Class A common stock. These RSUs represented a right to receive one share each and carried no expiration date.
After this compensation-related conversion, Gonzales directly holds 201,789 shares of Evolv Class A common stock. The filing does not show any open-market purchases or sales, only the exercise of equity awards previously granted to him.
Evolv Technologies Holdings, Inc. director Mark J. Sullivan exercised restricted stock units into common shares. On June 17, 2026, 27,050 RSUs vested in full and were converted into 27,050 shares of Class A common stock at no exercise price. Following this equity award vesting and conversion, he holds 242,628 Class A shares directly, with no same-day sale reported.
Evolv Technologies Holdings director Henrik Kuhl reported routine equity compensation activity. On June 18, 2026, he received a grant of 28,318 Restricted Stock Units, each representing one share of Class A common stock. These RSUs vest in full at the earlier of June 18, 2027 or the day immediately before the next annual meeting.
On June 17, 2026, 9,291 RSUs vested in full and were exercised into 9,291 shares of Class A common stock at no cash exercise price. Following these transactions, he directly holds 9,291 shares of Class A common stock from this exercise, along with the new 28,318-unit RSU award subject to future vesting.
Evolv Technologies Holdings director Kevin M. Charlton reported equity compensation and related share activity. He received a grant of 28,318 Restricted Stock Units (RSUs) on Class A common stock that will vest in full at the earlier of June 18, 2027 or the day immediately before the company’s next annual meeting. On June 17, 2026, a prior award of 27,050 RSUs vested in full, and these units were converted into the same number of Class A common shares, increasing his direct holdings to 359,010 shares. He also reports 44,081 Class A common shares held indirectly through an IRA.
Evolv Technologies Holdings director Richard A. Shapiro reported equity compensation activity in the form of restricted stock units (RSUs) and common stock. He received a grant of 28,318 RSUs, each representing a contingent right to one share of Class A common stock. These RSUs will vest in full at the earlier of June 18, 2027 or the day immediately preceding the company’s next annual meeting date.
Separately, 27,050 RSUs vested in full on June 17, 2026 and were exercised into 27,050 shares of Class A common stock, after which he held 79,565 shares directly. The filing also shows indirect holdings of 16,400 shares held by his spouse in a retirement plan, 22,500 shares held by a trust for which he has voting and dispositive power over the share-based assets, and 30,000 shares held by his spouse.
Evolv Technologies Holdings director Kimberly H. Sheehy reported equity compensation activity, not open-market trading. On June 18, 2026, she received a grant of 28,318 Restricted Stock Units, each representing a contingent right to one share of Class A common stock.
The new RSUs will vest in full at the earlier of June 18, 2027 or the day immediately preceding the issuer's next annual meeting date. On June 17, 2026, 27,050 RSUs vested and were exercised into 27,050 shares of Class A common stock. Following these transactions, Sheehy directly holds 170,085 common shares.
Evolv Technologies Holdings director Neil Glat reported equity compensation activity and an option-equivalent exercise. He received a grant of 28,318 Restricted Stock Units, each representing one share of Class A common stock. These RSUs will vest in full at the earlier of June 18, 2027 or the day immediately preceding the company’s next annual meeting date.
Separately, RSUs covering 27,050 shares vested in full on June 17, 2026 and were exercised into 27,050 shares of Class A common stock. Following these transactions, Glat directly holds 243,600 shares of Class A common stock and 28,318 outstanding RSUs.
Ellenbogen Michael reported acquisition or exercise transactions in this Form 4 filing.
Evolv Technologies Holdings, Inc. director Michael Ellenbogen reported an award of 28,318 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the company’s Class A common stock and has no expiration date.
The 28,318 RSUs will vest in full on the earlier of June 18, 2027 or the day immediately before the company’s next annual meeting date. Following this grant, Ellenbogen holds 28,318 RSUs directly, reflecting a compensation-related equity award rather than an open-market share purchase.
Evolv Technologies Holdings director Michael Ellenbogen exercised stock options and sold shares on the same day. He exercised options to acquire 80,745 shares of Class A Common Stock at an exercise price of $0.24 per share, then sold 80,745 shares at a weighted average price of $6.21 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan entered into on June 12, 2025. Following these transactions, he holds 2,083,961 shares of Class A Common Stock directly and 151,135 shares indirectly through the Family Horizon Trust, and retains 977,759 stock options.